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NOTE
BROADENING THE SCOPE OF BIOTECHNOLOGY INVENTIONS BY
DISCLOSING A SCIENTIFIC THEORY

Jeffrey L. Light

Much has been written about what is needed to enable the full scope for a
biotechnology invention.[1] The courts have also decided a substantial number of cases in
this area. Nevertheless, it is still difficult to advise an inventor on what to do to enable his
invention for a genus, where he has performed his experiments in one or a few species.
There are several reasons for this difficulty. First, the factors cited by courts to
determine the scope of enablement for an invention are either beyond the control of the
inventor or are uninformative in the context of biotechnology. Second, the factors are
only illustrative so they cannot be depended upon with any certainty. Third, the existing
case law is highly fact-dependent with no bright line rules. Finally, commentators writing
about the application of the enablement requirement to biotechnology inventions have
mostly described Federal Circuit cases, without finding unifying themes or analyzing the
decisions of district courts.
Although the Wands factors by themselves are not particularly helpful to
inventors, adding a description of the scientific theory underlying the invention may help
increase the scope of enablement. The presence of a scientific theory works to increase
[*88*] the scope of enablement where it reduces the amount of experimentation
necessary or increases the predictability of the invention. Many district courts already

consider the presence or absence of a scientific theory when evaluating the Wands
factors, though not explicitly. On the other hand, the Supreme Court and Federal Circuit
have placed limits on the ways in which the presence or absence of a scientific theory
may be considered.
Part I of this note explains what the enablement requirement is and why it has
been difficult to determine the scope of enablement for biotechnology inventions. The
remainder of Part I describes the Federal Circuit’s decision in In re Wands, the case most
frequently relied on in assessing whether the enablement requirement has been met. Part
II of this note explains why the Wands factors do not provide much guidance for advising
biotechnology inventors attempting to claim a genus. Part III explains how the disclosure
of a scientific theory may increase the scope of enablement. This section details the
consideration of a scientific theory by both district and appellate courts. Part IV
concludes with a recommendation that, when possible, inventors should describe in the
specification the scientific theory underlying their inventions.

I. BACKGROUND

A. The Enablement Requirement

[*89*] The statutory basis for the enablement requirement is the first paragraph of
35 USC § 112. This provision states that the specification must contain a written
description of the invention, and of the manner and process of making and using it, in
such full, clear, concise, and exact terms as to enable any person skilled in the art to
which it pertains, or with which it is most nearly connected, to make and use the same.
The enablement requirement is used in two contexts. First, 35 USC § 112 requires
enablement per se, meaning that the disclosure must allow a person of ordinary skill in
the art to make and use the invention. Although not explicitly stated in the statute, courts
have read this to mean that the invention must be enabled to a person of ordinary skill in
the art without “undue experimentation.”[2] Second, it requires the scope of enablement
provided in the disclosure to persons of ordinary skill in the art must be commensurate
with the scope of the claims.[3] In this case, the disclosure enables some parts of the
invention, but does not enable other parts.
The scope of enablement doctrine serves several important purposes by
preventing inventors from obtaining patents that cover more than they invented. An
overly broad claim that is not fully enabled stifles innovation in that area of research
because other scientists in the field are afraid of infringing the patent.[4] Additionally,
granting broad claims rewards those who invent a relatively small advance at the expense
[*90*] of those who make large, but slightly less timely advances.[5] Therefore, scope of
enablement is an essential part of the bargain between the patentee and society.
These policy goals are mitigated by the applicant’s presumptive right to a patent
as granted by 35 USC § 102. As a result of this presumption, the burden is initially on the
examiner during prosecution to show that the applicant has not met the requirements for

patentability, including proper scope of enablement.[6] If successful in meeting its burden,
the burden shifts to the applicant to show that the claims are fully enabled.[7] Once the
patent issues, the presumption that the whole patent instrument is valid creates a
presumption that the claims are of a scope commensurate with the specification.
Therefore, the party challenging the patent carries the burden of showing by clear and
convincing evidence that the scope of enablement is less than what is claimed.

B. The Lack of a Bright Line Rule for Enablement

The issue of enablement is highly fact-specific, without any bright line rules for
guidance. This ad hoc approach is described by Judge Newman in her dissent in In Re
Wands, where she states, “As illustrated in extensive precedent on the question of how
much experimentation is ‘undue,’ each case must be determined on its own facts.”[8] This
[*91*] case-by-case approach to enablement offers little predictability to inventors trying
to fulfill the enablement requirement.
The lack of a bright line rule is especially problematic in biotechnology. When an
inventor describes several species, but claims a genus, she may find, for various reasons
related to the nature of biotechnology, that the scope of enablement is limited to less than
the full genus. For example, the genus may be broken down into classes in different
ways. If all of the inventor’s experimentation was performed in one organism, an accused
infringer might claim that the invention is enabled only for the organism described,

despite a claim applying to all organisms. Even if the inventor’s experiments were
performed in several organisms, such as different types of bacteria, the opposing party
might claim that the invention is not enabled for more complex cells, such as eukaryotes.
For an invention embodied in a plant, the examiner may take the position that the
invention is enabled for dicotyledonous but not the more commercially valuable
monocotyledonous plants. Monocots and dicots are two types of flowering plants which
have one leaf during early development (monocots) or two leaves (dicots).[9]
These dichotomies present difficulties for inventors for several reasons. First,
there are many different classifications in biology, and it may not take an infringer much
creativity to find a class of organisms for which the invention has not been enabled.
Second, biotechnology is a highly unpredictable art. As a result, it is difficult for an
inventor to demonstrate that his invention will work for all organisms contained in the
genus. Third, the life sciences often focus on model organisms such as E. coli or yeast,
which are not commercially valuable. These model systems are chosen because they are
relatively easy to work with and share many characteristics of more complex [*92*]
organisms.[10] However, once a discovery has been made in a model organism, inventors
have many incentives to file their patent application as soon as possible.[11] Without
performing additional experiments to confirm that the invention works in a broader class
of cells, it is difficult to know whether it will work in other cells, absent some guiding
principle.
One potential solution is to file an application immediately, but continue to
experiment until a guiding principle is discovered. Even if the inventor is successful in

this endeavor, she may still face obstacles during prosecution and litigation under the
enablement requirement.
First, the scientists performing the experiment may possess a much higher than
ordinary degree of skill in the art. Because the enablement test requires a person of
ordinary skill in the art to be able to use the invention without undue experimentation,
such successes by a person of higher skill may not be relevant.
Second, the experiment may be successful only after an undue amount of
experimentation. Publication of such results may allow a person of ordinary skill in the
art to use the invention without undue experimentation. However, enablement requires
that a person of ordinary skill be able to use the invention at the time of filing.[12]
Therefore, this result would work against the inventor because it would show that undue
experimentation was required at the time of filing.
[*93*] Finally, if the experiments are unsuccessful, these failures may be counted
against the inventor in determining the scope of enablement.[13]

C. The Standard Provided by In re Wands

In In re Wands, the Federal Circuit set forth a series of factors to be used in
determining whether the enablement requirement has been met.[14] The court held that for
unpredictable arts such as biotechnology, undue experimentation is determined by a
standard of reasonableness which can be assessed by examining eight factors: (1)

quantity of experimentation necessary (2) the amount of direction or guidance presented;
(3) the presence or absence of working examples; (4) the nature of the invention; (5) the
state of the prior art; (6) the relative skill of those in the art; (7) the predictability or
unpredictability of the art; and (8) the breadth of the claims.[15]
Subsequent decisions have addressed how the factors should be applied. First,
although In re Wands concerned enablement per se, the Federal Circuit has sanctioned
the use of these factors to determine the scope of enablement.[16] However, none of the
decisions applying the Wands factors has discussed how each factor should be weighed.
As a result, it is difficult for an inventor to know how much disclosure is necessary to
enable the full scope of his claims. Second, the Federal Circuit has held that the Wands
[*94*] factors are merely illustrative.[17] Therefore, a court is free to choose which factors
to examine, to create new factors to apply, or to ignore factors that are present. Third,
although In re Wands was an ex parte case, the factors also apply to inter partes litigation
because in both instances, the proper inquiry focuses on what would have been enabled at
the time of filing.[18]

II. THE WANDS FACTORS

The Wands factors by themselves are of little use in helping an applicant
determine how much disclosure is necessary to enable a genus without performing
experiments on every species within that genus. One reason that the Wands factors are

not helpful to applicants is that several of the factors are beyond the control of the
applicant. Therefore, the Wands factors by themselves do not allow an inventor to
increase the scope of enablement by performing additional experiments or adding more
information to the specification. The remaining factors are so vague that an applicant
cannot be reasonably certain what she needs to do to enable the full scope of her
invention.
[*95*] This part of the note will analyze the Wands factors through Federal
Circuit opinions rather than district court opinions because enablement is ultimately a
question of law that is reviewed de novo on appeal.[19]

A. Factors Over Which Applicant Has No Control

1. Quantity of Experimentation Needed

The factor “quantity of experimentation needed” is a misnomer. Discussing In re
Wands, the Federal Circuit in Johns Hopkins University v. CellPro, Inc. stated that undue
experimentation is “not merely quantitative,” and that a considerable amount of
experimentation is permissible.[20] The resolution of this apparent contradiction is that the
court is concerned with the amount of non-routine experimentation, not the total quantity
of experimentation. Some technologies are inherently unpredictable and require much
repetition, even with a detailed disclosure.[21] Unfortunately, the inventor has no control

over how much repetition is inherent in the technology. The inventor also cannot control
whether or not the experimentation is routine. Whether or not experimentation is routine
depends on what is well-known in the art at the time of filing.[22] Because an inventor
[*96*] cannot change what is well known in the art at the time of filing through the
addition of information to his disclosure, this factor offers little help to the inventor.

2. State of the Prior Art

The existence of prior art at the time of filing is beyond the control of the
patentee. However, the inventor has some control over this factor because he can alert the
United States Patent and Trademark Office (PTO )or court by citation in his application
to the existence of prior art that that tends to show that his invention is broadly enabled.
Nevertheless, there are limitations on the use of this factor.
Prior art enjoys only a limited role in supporting enablement. Prior art can only be
used to fill in small gaps in the disclosure. [23] In Genentech II, the patentee strongly relied
on prior art to expand the scope of enablement for his invention.[24] The court rejected this
extensive use of prior art, holding that prior art can only be used to supply minor details
which are not described in the specification.[25] The court stated that prior art is “not a
substitute for a basic enabling disclosure.”
Even if the patentee is able to describe prior art that is helpful, by citing extensive
prior art to describe his invention, he may make his invention appear to have been

obvious.[26] Therefore, not only does the inventor have no control over the state of the
[*97*] prior art at the time of filing, an attempt to demonstrate the existence of such prior
art may be irrelevant or even harmful to the applicant.

3. Breadth of the Claims

The claims discussed in this note are broad because this note concerns how to
claim a genus where only species are disclosed.

B. Factors Which Are Too Vague to be Helpful

1. Presence or Absence of Working Examples

Although the Federal Circuit has indicated that it believes this factor is important,
it has not provided much guidance on how it should be applied. The question of how
many and what kinds of examples are needed is left unanswered.[27]
[*98*] The court in Enzo II also acknowledges the difficulty in evaluating the
presence or absence of working examples, stating that a “recurring problem is whether a

specification that sets forth a single or a limited number of examples can be enabling of
broad claims when the subject matter concerns biological materials or reactions, which
are generally considered unpredictable.”[28] More recently, the court in Amgen, Inc. v.
Hoechst Marion Roussel has suggested that a single example is indeed enough, provided
that “any gaps between the disclosures and the claim breadth could be easily bridged.”[29]
Reconciling these two views on the use of working examples highlights the uncertainties
that inventors face in trying to determine how much disclosure is sufficient.

2. Amount of Direction or Guidance Presented

There are many examples in which the court articulates how to recognize an
insufficiency of guidance, but fails to explain how much direction is enough. The court in
Enzo II cautions that “[t]ossing out a mere germ of an idea does not constitute enabling
disclosure.”[30] Unfortunately, it does not describe how much disclosure is enough.

3. Relative Skill / Predictability of the Art

[*99*] Both relative skill in the art and the predictability of the art are ambiguous
because court cases are divided as to how narrow the relevant field of art should be. In

some cases, the field of art is construed as biotechnology in general, and therefore the art
is regarded as having a high level of skill and a high degree of unpredictability.[31] In
other cases, the relevant field of art is a subfield of biotechnology. [32] Some subfields of
biotechnology are highly predictable, while others require a relatively low level of
skill.[33]
The level of ordinary skill may be hard to ascertain where multiple fields are
involved. Some fields such as genetic engineering are highly specialized, and the
invention therefore requires skill in several specializations. The court in Enzo II held that
where an invention combines different specializations, the invention must be enabled for
the “adepts of each art.”[34] As a result, an inventor may face considerable difficulty in
trying to determine the relative skill of one in the art.
Even if the inventor correctly determines in what field of art the court will place
his invention in, there are additional uncertainties that arise in considering the
predictability of the invention. Lack of predictability may be “not attributable to a failure
of disclosure,” but rather to the fact that the “technique was not foolproof.”[35] This
statement suggests that a certain amount of the unpredictability inherent in the technology
will not be counted against the patentee. Unfortunately, the Federal Circuit does not
provide a test for whether the unpredictability is the fault of the patentee. Thus, to the
[*100*] extent that the unpredictability is inherent in the technology, the patentee has no
control over it.

4. Nature of the Invention

This factor is virtually never referred to explicitly, presumably because it is too
ambiguous. In one of the few instances in which it was explicitly mentioned, Plant
Genetic Systems, N.V. v. Dekalb Genetics Corp., [36] the court found the consideration of
this issue to be moot. Plant Genetic Systems had argued that the pioneering nature of the
invention must be considered in determining the scope of enablement and that the district
court erred by not taking it into account.[37] The Federal Circuit rejected this argument,
holding that the district court did not need to make such a finding.[38] As a result, it is
unclear how applicants should consider this factor in writing their disclosure.

III. GETTING THE FULL BREADTH OF CLAIMS

[*101*] Despite the problems with the Wands factors, adding certain information
to the disclosure increases the chances that a court will find the full breadth of the claims
to be enabled. The information that should be included is the scientific theory underlying
the invention. The theory can take many forms, including a description of the cellular or
biochemical mechanism by which the invention works. However, in order to enable the
species not already described, the theory must decrease the amount of experimentation
needed or increase the predictability of the invention. In this way, the inclusion of a

scientific theory allows the inventor to have more control over how the Wands factors
will be applied to his patent.
District courts already frequently consider the presence or absence of a scientific
theory when evaluating the Wands factors. Part A of this section examines how district
courts have analyzed the presence or absence of a scientific theory in biotechnology
cases. Part B discusses the appellate cases that provide the limits on how the presence or
absence of a scientific theory may be used.

A. District Courts’ Consideration of Scientific Theory

District courts have frequently considered the presence or absence of a scientific
theory offered by either side as a factor in determining the scope of enablement in
biotechnology cases. This note examines cases in which the issue is the scope of
enablement and not enablement per se. That is, the claims cover some subject matter that
[*102*] is indisputably enabled, and some subject matter that may or may not be enabled.
The presence of a scientific theory or mechanism of action may increase the scope of
enablement by reducing the amount of experimentation needed and increasing the
predictability of the invention.[39] In contrast, a scientific theory offered by a defendant
may narrow the scope of enablement by showing differences between the particular
species described and other species in the genus. Such a showing of differences would

reduce the scope of enablement if additional experimentation would be needed to use the
invention in the non-disclosed species.
Although many commentators have analyzed Federal Circuit case law on this
topic, little has been written about how decisions are made at the district court level.[40]
This is striking because although enablement is a matter of law, it is based on underlying
factual determinations.[41] This section will review the district court cases which have
applied this factor.
The cases cover situations in which the patentee, the accused infringer, both, or
neither offer a scientific theory. Even in the cases where the patentee produces evidence
of a theory at trial, the relevance of this theory can depend on how the theory is
presented. The theory is more likely to be considered where it was disclosed in the
specification, either explicitly or by reference. It is less likely to be considered where it
was not disclosed in the patent, but instead the patentee argues that it was known to exist
by one of ordinary skill in the art at the time of filing.
An important theme that occurs throughout the cases is whether the theory
presented by either party affects the predictability of the invention. In this way, the
[*103*] scientific theory factor allows at least one of the Wands factors to offer guidance
as to how to enable a broad genus. Even though a scientific theory is not required, it helps
broaden the scope of enablement for the invention to the extent that it renders the
technology more predictable. Thus, a scientific theory is more likely to be needed in an
unpredictable field like biotechnology.

1. Hopkins v. CellPro

In Johns Hopkins University v. Cellpro, Inc., the patentee Hopkins discloses in its
specification the scientific theory underlying its invention.[42] The Hopkins patent teaches
how to use one antibody to an antigen, along with a description of the biochemical
mechanism by which the antibody attaches to the antigen.[43] This mechanism represents
Hopkins’ theory and, it argues, allows Hopkins to claim all antibodies against that
antigen because the same mechanism is common for all the members of that genus. The
court explains that its finding of enablement is based in part on the fact that “the
specification describes the entire fusion process.”[44] CellPro does not offer any countertheory or refutation of Hopkins’s theory. As a result, there is no dispute as to whether
Hopkins’s theory is empirically correct. This case therefore represents straightforward
evidence that district courts do look to scientific theory as a factor of enablement.

[*104*] 2. Gentech v. Novo Nordisk

Genentech v. Novo Nordisk[45] is similar to CellPro I in that the patentee has a
scientific theory and the accused infringer does not present a counter-theory or refute the
validity of the patentee’s theory. What is different about this case is that the theory is not

described in the specification of the patent. The theory is described in the literature, some
of which is explicitly referenced by the patent and some of it which is not.
The disclosed species in this case is a method for purifying hGH by the use of one
proteolytic enzyme, trypsin. Genentech argues that because all proteolytic enzymes are
similar in their action, the claims of their patent to all proteolytic enzymes are enabled by
the disclosure of using a single enzyme. The theory that all proteolytic enzymes share a
common mechanism of action is described in various articles that were available at the
time of filing. There are two subclasses of proteolytic enzymes, exopeptidases and
endopeptidases, and the literature describes how they are similar. The literature, some
referenced in the patent and some not, describes very specifically what each enzyme does
and how it works. The district court does not distinguish between referenced articles and
those that were not. It considers both in reaching its conclusion.
The consideration of the scientific theory as a factor in Genentech relies on the
extent to which it makes the technology more predictable. Here, unlike CellPro I, the
accused infringer challenges the validity of the scientific theory by arguing that
Genentech had not actually used its invention with any other enzymes, and therefore
[*105*] could not back up its theory with evidence.[46] Thus, there is a dispute of fact
over the validity of the scientific theory. The court makes a factual finding about the
correctness of the scientific theory when it states that "the activities of exopeptidases and
endopeptidases are the same."[47] The court does not find convincing the fact that none of
these other enzymes has actually been tested. Having found the theory convincing, the
court concludes that the claims are enabled for the entire genus because they make the
use of other enzymes easily predictable.[48]

3. Amgen v. Hoechst

In Amgen v. Hoechst[49], the patentee Amgen articulates a theory at trial, but that
theory was neither explicitly in the specification nor included by reference. However,
Amgen argues that such a theory would have been known to one of ordinary skill in the
art at the time of filing. The accused infringer offers no theory.
Dr. Lin of Amgen invented a process for producing erythropoietin in cells. The
specification discloses examples of how to use the invention in two different mammalian
cells. The invention is covered by two patents, one which claims the invention in all
[*106*] vertebrate cells, and another which claims the invention in all mammalian
cells.[50] (Mammalian cells are one type of vertebrate cell.)
Amgen’s theory for the first patent is that “all vertebrate cells produce and secrete
hormones by the same fundamental process” and for the second patent, that “mammalian
cells specifically, make proteins and process them in the same way.”[51] As the accused
infringer does not offer a counter-theory or refute the theories offered, the court accepts
the undisputed theory as fact. The court seems to indicate that it would have been
amenable to hearing evidence of a counter-theory when it notes that there is no record
that shows human cells are somehow different from other mammalian cells.[52] On this
point, Amgen’s expert testified that human cells could in fact be made to produce
EPO.[53]

4. PGS v. DeKalb

PGS v. DeKalb presents the opposite situation from the previous three cases. In
this case, the patentee does not have a scientific theory as to how any of the three possible
methods of carrying out its invention works.[54] For the first technique, the accused
infringer relies on the patentee’s lack of theory as a basis for its argument that the
invention is enabled for only a small set of plants. In the second method, the accused
infringer does have a scientific theory as to why the patent is not enabled with respect to
[*107*] that method. The third method is inoperable and therefore the court does not
address the matter of scientific theory.
The patent discloses a genetically engineered plant and provides examples of how
to perform the genetic manipulation in various dicotyledonous plants. However, the
claims read on all plants, including both monocotyledonous and dicotyledonous
species.[55] Because none of the techniques disclosed in the patent work in monocots,
PGS relies on techniques that would have been known to one skilled in the art at the time
of filing. At trial, PGS argues that three techniques, agrobacterium-mediated infection,
elctroporation and microprojectile bombardment were known to those skilled in the art at
the time of filing and could have successfully been used to transform monocot plants.
DeKalb is able to demonstrate nonenablement by stressing the fact that PGS did not
provide a scientific theory. It provides "clear and convincing evidence that the so-called

'monocot barrier' was still firmly in place”[56] by refuting the effectiveness of each of the
techniques.
Neither PGS nor DeKalb has a theory as to how agrobacterium-mediated
infection works at a cellular level. However, DeKalb is able to prove nonenablement by
this technique because it is able to demonstrate two things. First, it shows that the
technology is highly unpredictable.[57] Second, DeKalb shows that PGS does not have
any idea how the technology works, let alone a theory which might cure this
predictability problem.[58] DeKalb shows that the technology was unpredictable by
drawing out testimony from PGS’s expert that PGS conducted experiments after the
patent issued in order to figure out why agrobacterium in monocots did not work. This
also demonstrates [*108*] that PGS thought a theory would be helpful in determining
how to enable the invention for monocots. Additionally, DeKalb demonstrated the lack of
a theory by getting PGS to admit that the agrobacterium method is a “complete black
box.”[59] As a result, the court is convinced that the lack of a curative theory is an
important factor, stating that “[s]cientific research involves attempting to understand why
and how things – in this case biological processes – work.”[60] It therefore finds this
method does not provide enablement.
Although PGS does not have a theory as to how electroporation works, DeKalb
demonstrates why the technique will not work in monocots.[61] DeKalb’s scientist
achieved success with electroporation only in a special type of corn. Based on this
experiment, DeKalb’s scientist concluded that the experiment was successful in that
special strain of corn because it was able to reform its cell walls. However, "ordinary

corn cells would not reform the cell walls”[62] and therefore would not be susceptible to
electroporation.
Neither side has a theory on how the third technique, microprojectile
bombardment, works. However, this technique is inoperable and therefore the scientific
theory does not play a part in the court’s decision on this point.

5. Enzo Biochem v. Calgene, Inc.

[*109*] In Enzo Biochem v. Calgene, Inc.[63], both sides offer a scientific theory.
The patentee’s theory, however, is very general and does not render the invention more
predictable. The infringer’s theory on the other hand, explains how the invention works,
as well as why the method will only work in certain cells.
Enzo’s invention is a method for using antisense technology. The specification
discloses examples of using this method in three different genes in E.coli.[64] However,
the claims are much broader and read on all genes in all organisms. The main point of
dispute is whether Enzo’s disclosure enables the use of antisense in eukaryotic as well as
prokaryotic cells.
Enzo argues that the invention on its face is a “basic principle or theory.”[65] The
court accepts this argument, but finds the theory insufficient to fully enable the claims
because it does not reduce the unpredictability of the invention.

Enzo’s theory does not help to predict which cells are capable of being used for
antisense. Enzo’s expert states that the unpredictability is due to the “instability of
individual RNAs of the individual cells.”[66] Calgene’s expert expands on this statement
by testifying that case-by-case experimentation was necessary to figure out if antisense
would work in eukaryotes. Enzo’s expert later concedes that the technology is highly
unpredictable and describes it as “witchcraft.”[67]
Calgene takes its nonenablement argument a step further by offering its own
theory. Its expert testifies that antisense technology works only in prokaryotes because
"eukaryotic cells have 'posttranscriptional aberrant processing,' a process not found in
[*110*] prokaryotic cells."[68] This theory, therefore, is able to predict which cells can be
used with antisense technology. The court accepts this theory and its corresponding
predictions and states that there is no “credible evidence that success was achievable in
eukaryotic cells.”[69] Therefore a theory which does not reduce the unpredictability of an
invention is not of much value in demonstrating enablement.

6. Amgen v. Chugai

In Amgen, Inc. v. Chugai Pharmaceutical Co.,[70] neither the patentee, Amgen,
nor the accused infringer Chugai, offers a scientific theory as to how the invention works.
Although such disclosure is not required of either side, the district court considers the
absence of a scientific theory as a factor tending towards nonenablement.[71]

Amgen argues that the invention is less unpredictable than is alleged by Chugai,
but does not offer a scientific theory that would enable a scientist to predict the outcome
of an experiment. The claimed invention in this case is the gene coding for erythropoietin
(EPO )and all EPO analogs. Analogs are genes that have been altered, but still have many
of the same biological properties as the original gene. Amgen suggests that "a scientist
[*111*] might be able to predict the activity of some analogs but not others.”[72] It further
states that most analogs will have similar biological activity. Amgen therefore argues that
the invention is predictable without supporting that argument with a scientific theory.
Chugai refutes Amgen’s claim that the technology is predictable by pointing to
the lack of a scientific theory. Chugai argues that "scientists have not yet sorted out
which particular amino acid residue is required for biological activity, and the data is
incomplete.”[73] Had Amgen or another group of scientists figured out which amino acid
residue is important, this knowledge could have formed the basis for a theory that
presumably could have been used to increase the predictability of the technology. Chugai
strengthens this argument by having its own expert testify that “[t]here is no theory that
tells us what to look for.”[74] Chugai’s argument is that prediction requires a theory and
that there is no such theory currently available.
The court sides with Chugai. The court “relies in particular on the lack of
predictability in the art, as demonstrated by the testimony of Dr. Goldwasser and Dr.
Elliot.”[75] The court explains that the part of the testimony it is referring to is that
“according to Dr. Goldwasser, there is no theory which tells leading scientists in the field
what combination of amino acids will have the biological property claimed in the

patent.”[76] Thus, the lack of a theory renders the invention unpredictable and therefore
leads to a smaller scope of enablement.[77] On the flip side, a scientific theory that
[*112*] increases predictability in a generally unpredictable field like biotechnology
would also lead to a greater scope of enablement.

B. Limitations on how the presence or absence of a scientific theory may be used

A large number of cases establishes the principal that a scientific theory cannot be
required.[78] However, three themes are apparent from these cases. First, there is no
mention of whether a theory can be considered. Second, the theory need not be correct in
a strict scientific sense, provided that it increases the predictability or reduces the quantity
of experimentation needed. Finally, the articulation of a theory does not limit the scope of
the claims.

1. Theory as a consideration

Although a theory cannot be required, the question of whether an inventor who
provides a scientific theory can benefit from this disclosure is left open.[79] Newman v.
Quigg is frequently cited for the proposition that a scientific theory is not a requirement

[*113*] of patentability.[80] The court in this case stated that “it is not a requirement of
patentability that the inventor correctly set forth, or even know how or why the invention
works.”[81] In other words, the absence of a theory is not fatal to patentability. Other cases
that discuss scientific theory only prohibit its use as a requirement.[82]
Scientific theory has also been used as a consideration in other contexts. For
example, an examiner may rely on a scientific theory in rejecting an application as
obvious.[83] However, the examiner must not only explain the theoretical mechanism, but
also show that the theory would have led one of ordinary skill in the art to make the
claimed invention.[84] This analogy to nonobviousness is helpful for two reasons. First, it
suggests that Newman should not be read to eliminate scientific theory as a consideration.
Because the PTO uses scientific theory as a consideration for obviousness, it must not
believe that there are any cases that prohibit it from using scientific theory as a
consideration, rather than a requirement. Second, the application of scientific theory to
obviousness suggests how it might be applied to enablement. The Board held that
scientific theory may only apply to obviousness if it contributes to the determination of
whether the standard for obviousness is met. That is to say that the presence of a
scientific theory is not a helpful factor per se. In the context of enablement, similar logic
would suggest that a scientific theory would only be useful if it contributes to a
determination of the extent to which the factors defining scope of enablement have been
met. Thus, a scientific theory that increases the predictability of the invention or reduces
[*114*] the amount of experimentation needed would be considered in determining the
scope of enablement.

2. Correctness

The court’s statement in Newman also only addresses the requirement for a
correct theory. The inventor does not need to “correctly set forth a theory.”[85] In turn,
Newman relies on Diamond Rubber Co. of New York v. Consolidated Rubber Tire Co.
which states that “it is not necessary that [the inventor] understand or be able to state the
scientific principles underlying his invention, and it is immaterial whether he can stand a
successful examination as to the speculative ideas involved.”[86]
There are several ways to interpret these two quotes together. First, if the inventor
need not set forth a correct theory, yet it is immaterial whether or not his theory is
correct, then the inventor need not submit any theory. While this may be an accurate legal
statement, it does not provide a better understanding of the relevance of correctness. In
fact, it makes the word “correctly” superfluous in the statement that an inventor need not
“correctly set forth a theory.” A second reading that is not incompatible with either
statement is that a theory may be required, but a correct theory cannot be required. This
would imply that there is a requirement that a patentee submits a theory, but it is just a
formality, as its correctness is irrelevant. This is an absurd result which finds support
[*115*] nowhere in patent law. A third reading makes more sense. Although correct
theory is not required, neither statement speaks to whether any theory offered may be
considered. There are several reasons to believe that a scientific theory may be
considered, if offered. When the court says that a successful examination of the

“speculative ideas” is irrelevant, the plain meaning is the “theoretical rather than
demonstrable”[87] ideas. In other words, if a scientific theory is offered, the empirical
predictions may be considered, but there cannot be a requirement that the underlying
logic of the hypothesis is correct. This is in accord with the district court cases which
considered scientific theory as a factor, but only to the extent that they can demonstrably
reduce uncertainty.[88]
This interpretation which differentiates empirical from theoretical aspects of
scientific theory is also supported by case law and PTO rules. In In re Grose, the court
held that the use of a scientific theory, in order to be relevant, must be accompanied by
evidence that demonstrates the existence and meaning of that theory.[89] Therefore, the
influence of a scientific theory should depend on its empirical and demonstrable aspects
and not its underlying logic. Additionally, this case and rule confirm that a scientific
theory may be considered in determining patentability. [90]

3. Impact of theory on claims

[*116*] The patentee will not be penalized for including a theory in the
specification that is narrower than the claims because the court will not use the theory to
limit the scope of the claim. The court reasoned that because a theory is not required, it
should not be used to limit the scope of a claim.[91] This is consistent with several cases
that have held that limits in the specification should not be imported into the claims.[92]

IV. Conclusion

Inventors should describe the cellular or biochemical mechanism by which their
invention works. This information, if it can decrease the unpredictability or amount of
experimentation needed, can increase the scope of enablement. It is one of the few
affirmative steps that an applicant can make at the time of filing which can influence the
way the Wands factors will be applied. Without a theory, the scope of enablement will be
determined in an unpredictable, fact-specific manner using the Wands factors or any
other factors the district court believes to be relevant. Additionally, the absence of a
theory provided by the patentee may negatively impact the scope of enablement where
the patent is challenged by a party with its own theory that demonstrates that undue
experimentation would be needed to use the invention in the non-disclosed species.
[*117*] However, an inventor must recognize that there are limitations to how the
presence or absence of a scientific theory may be treated by the courts. Although the
theory does not need to live up to the stringent standards of peer-reviewed science, it
must either be able to increase the predictability of the circumstances in which the
invention will work or else decrease the amount of experimentation needed to use the
invention. The sooner and more explicitly an inventor discloses the theory, the better. A
theory included in the specification is much more likely to be looked upon favorably by a
court then one that is first presented at trial.

Finally, the inventor need not worry that a theory included in the specification
will be used to limit his claims. Therefore, whenever doubts arise as to whether the
claims in a biotechnology patent are fully enabled, an inventor should be advised that the
addition of a scientific theory is a good insurance policy.
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